Teva Pharmaceutical Industries (TEVA) Receivables - Net (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Receivables - Net for 18 consecutive years, with $3.4 billion the latest figure, recorded in Q1 2026.

• Quarterly Receivables - Net changed 0.27% year-over-year to $3.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 billion (changed 0.27% YoY) and the FY2025 annual result came in at $3.7 billion, up 21.25% from the prior year.
• Receivables - Net declined to $3.4 billion in Q1 2026 per TEVA's latest filing, from $3.7 billion in the prior quarter.
• Over the last five years, Receivables - Net for TEVA reached as high as $4.5 billion in Q2 2022 and fell as low as $3.1 billion in Q4 2024.
• A 5-year average of $3.6 billion and a median of $3.5 billion in 2023 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2023 — Receivables - Net slipped 20.85% — and 2025, when it gained 21.25%.
• Year by year, Receivables - Net stood at $3.7 billion in 2022, then dropped by 7.79% to $3.4 billion in 2023, then fell by 10.24% to $3.1 billion in 2024, then gained by 21.25% to $3.7 billion in 2025, then decreased by 8.52% to $3.4 billion in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $3.4 billion, $3.7 billion, and $3.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.